Which form of therapy has a goal of helping the client determine how to improve their life rather than focusing on the negative?

Choice A reason: The forming phase is the initial stage of group development. During this phase, members are typically anxious and cautious as they try to understand the group’s purpose and their role within it. Concerns about acceptance, belonging, and potential rejection are prominent. Members may be hesitant to share openly and are focused on establishing safety and trust.

Choice B reason: The storming phase is characterized by conflict and power struggles. Members begin to assert their individual needs and challenge group norms or leadership. While tension may arise, the primary concern shifts from rejection to negotiating roles and influence within the group.

Choice C reason: In the norming phase, members begin to establish cohesion and shared norms. Trust increases, and the fear of rejection diminishes. Members feel more secure and begin to collaborate more effectively.

Choice D reason: The performing phase is marked by high-functioning collaboration. Members are comfortable with each other and focused on achieving group goals. Concerns about rejection are no longer central at this stage.

Choice A reason: While melatonin is generally considered safe for short-term use, it has clinically significant interactions with several medications, including immunosuppressants. It can stimulate immune function, which may counteract the effects of immunosuppressive therapy. Therefore, this response is overly dismissive and potentially unsafe.

Choice B reason: Melatonin can interfere with immunosuppressive therapy by enhancing immune activity, which is counterproductive in conditions like rheumatoid arthritis where immunosuppression is often necessary. This makes it contraindicated or at least a cautionary supplement in such contexts. The PMHNP should recognize this and advise accordingly.

Choice C reason: While deferring to the primary care provider may seem prudent, the PMHNP is qualified to assess drug interactions and should take responsibility for evaluating the safety of melatonin in this context. This response lacks clinical assertiveness.

Choice D reason: Suggesting a benzodiazepine as a replacement for melatonin without assessing the client’s full psychiatric and medical profile is inappropriate. Benzodiazepines carry risks of dependence and sedation and are not a direct substitute for melatonin in most cases.